Key facts
- This page summarizes Robert E. Radway's Form 4 filing for CDK Global, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Nov 2021, 17:32.
Robert E. Radway - 15 Nov 2021 Form 4 Insider Report for CDK Global, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 15 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Nov 2021, 17:32:36 UTC
- Next SEC filing
- 06 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lee J. Brunz, Power of Attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Radway filed Form 4 for CDK Global, Inc. on 16 Nov 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,761
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 37,677
- Date
- 15 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
CDK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,053
- Change %
- +5.4%
- Price
- $0.000000
- Shares after
- 39,730
- Date
- 15 Nov 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported transaction reflects the grant of Restricted Stock Units under the Issuer's 2014 Omnibus Award Plan and represents a like number of shares of the Issuer's common stock. These Restricted Stock Units vest in full at the earlier of November 11, 2022 and the Issuer's next annual meeting of stockholders. Upon vesting these Restricted Stock Units will be deferred and settled in shares of the Issuer's common stock 180 days after the date the Reporting Person ceases to be a member of the Issuer's board of directors.
Footnote F2
The reported transaction reflects the grant of Deferred Stock Units under the Issuer's 2014 Omnibus Award and represents a like number of shares of the Issuer's common stock. The Deferred Stock Units vest in full upon grant and will settle in shares of the Issuer's common stock.